AEON Biopharma (AEON) Competitors $0.65 +0.00 (+0.08%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends AEON vs. PYXS, ASMB, ORMP, TLSA, TNXP, MIST, COYA, EPRX, NVCT, and RANIShould you be buying AEON Biopharma stock or one of its competitors? The main competitors of AEON Biopharma include Pyxis Oncology (PYXS), Assembly Biosciences (ASMB), Oramed Pharmaceuticals (ORMP), Tiziana Life Sciences (TLSA), Tonix Pharmaceuticals (TNXP), Milestone Pharmaceuticals (MIST), Coya Therapeutics (COYA), Eupraxia Pharmaceuticals (EPRX), Nuvectis Pharma (NVCT), and Rani Therapeutics (RANI). These companies are all part of the "pharmaceutical preparations" industry. AEON Biopharma vs. Pyxis Oncology Assembly Biosciences Oramed Pharmaceuticals Tiziana Life Sciences Tonix Pharmaceuticals Milestone Pharmaceuticals Coya Therapeutics Eupraxia Pharmaceuticals Nuvectis Pharma Rani Therapeutics Pyxis Oncology (NASDAQ:PYXS) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, community ranking, dividends, institutional ownership, media sentiment, valuation and risk. Do analysts prefer PYXS or AEON? Pyxis Oncology currently has a consensus target price of $9.43, indicating a potential upside of 457.90%. AEON Biopharma has a consensus target price of $5.00, indicating a potential upside of 669.23%. Given AEON Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe AEON Biopharma is more favorable than Pyxis Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pyxis Oncology 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89AEON Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, PYXS or AEON? Pyxis Oncology has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.Comparatively, AEON Biopharma has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500. Is PYXS or AEON more profitable? AEON Biopharma's return on equity of 0.00% beat Pyxis Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Pyxis OncologyN/A -36.22% -28.76% AEON Biopharma N/A N/A -994.63% Does the MarketBeat Community favor PYXS or AEON? Pyxis Oncology received 20 more outperform votes than AEON Biopharma when rated by MarketBeat users. However, 100.00% of users gave AEON Biopharma an outperform vote while only 82.35% of users gave Pyxis Oncology an outperform vote. CompanyUnderperformOutperformPyxis OncologyOutperform Votes2882.35% Underperform Votes617.65%AEON BiopharmaOutperform Votes8100.00% Underperform VotesNo Votes Which has higher valuation and earnings, PYXS or AEON? AEON Biopharma has lower revenue, but higher earnings than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPyxis Oncology$16.15M6.22-$73.79M-$1.03-1.64AEON BiopharmaN/AN/A-$36.63M$0.183.61 Does the media refer more to PYXS or AEON? In the previous week, Pyxis Oncology had 9 more articles in the media than AEON Biopharma. MarketBeat recorded 10 mentions for Pyxis Oncology and 1 mentions for AEON Biopharma. Pyxis Oncology's average media sentiment score of 0.58 beat AEON Biopharma's score of 0.00 indicating that Pyxis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pyxis Oncology 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AEON Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders believe in PYXS or AEON? 39.1% of Pyxis Oncology shares are owned by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are owned by institutional investors. 9.8% of Pyxis Oncology shares are owned by insiders. Comparatively, 23.5% of AEON Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryPyxis Oncology and AEON Biopharma tied by winning 8 of the 16 factors compared between the two stocks. Ad DTIWhy I'm telling friends to avoid gold stocksBack in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. Get AEON Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AEON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AEON vs. The Competition Export to ExcelMetricAEON BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.98M$6.57B$5.10B$9.08BDividend YieldN/A2.97%4.88%4.21%P/E Ratio3.6110.5090.8317.14Price / SalesN/A195.361,112.01116.85Price / CashN/A57.1642.0237.88Price / Book-0.165.104.774.78Net Income-$36.63M$151.51M$119.70M$225.60M7 Day Performance-3.56%-2.11%-1.86%-1.23%1 Month Performance16.28%-3.11%11.45%3.07%1 Year Performance-88.50%11.53%30.43%16.48% AEON Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AEONAEON Biopharma2.4528 of 5 stars$0.65+0.1%$5.00+669.2%-88.4%$25.98MN/A3.615News CoverageGap DownPYXSPyxis Oncology2.1742 of 5 stars$1.67+2.8%$10.00+500.6%-2.9%$99.02MN/A-1.5760Analyst ForecastNews CoveragePositive NewsASMBAssembly Biosciences3.8138 of 5 stars$15.50+0.8%$35.00+125.8%+64.6%$98.52M$28.33M0.00100News CoverageGap DownORMPOramed Pharmaceuticals1.6829 of 5 stars$2.42-2.0%N/A+8.2%$97.55M$1.34M22.4510Analyst UpgradeTLSATiziana Life Sciences1.2056 of 5 stars$0.91-2.9%N/A+30.8%$96.33MN/A0.008Gap DownTNXPTonix Pharmaceuticals3.6123 of 5 stars$0.51+113.1%$53.50+10,337.0%-95.0%$95.80M$11.29M0.00103High Trading VolumeMISTMilestone Pharmaceuticals1.6381 of 5 stars$1.80-0.3%$12.00+568.5%-34.8%$95.72M$1M-2.2230COYACoya Therapeutics2.1472 of 5 stars$5.69-3.4%$16.25+185.6%-23.7%$95.06M$9.55M-9.066Analyst ForecastPositive NewsGap DownEPRXEupraxia Pharmaceuticals2.2141 of 5 stars$3.48+1.2%$9.00+158.6%N/A$94.94MN/A-4.7829Positive NewsNVCTNuvectis Pharma3.2504 of 5 stars$4.86+3.4%$21.00+332.1%-45.3%$93.90MN/A-4.058Positive NewsRANIRani Therapeutics3.4495 of 5 stars$1.63-1.8%$11.71+618.7%-55.1%$93.38M$2.72M-1.57110Positive News Related Companies and Tools Related Companies PYXS Alternatives ASMB Alternatives ORMP Alternatives TLSA Alternatives TNXP Alternatives MIST Alternatives COYA Alternatives EPRX Alternatives NVCT Alternatives RANI Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AEON) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AEON Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AEON Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AEON Stock Alerts